138 related articles for article (PubMed ID: 23941814)
1. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
4. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
5. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
8. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
9. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Wada Y; Yoshida K; Suzuki T; Mizuiri H; Konishi K; Ukon K; Tanabe K; Sakata Y; Fukushima M
Int J Cancer; 2006 Aug; 119(4):783-91. PubMed ID: 16557585
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Ide H; Kikuchi E; Hasegawa M; Hattori S; Yasumizu Y; Miyajima A; Oya M
Cancer Med; 2013 Aug; 2(4):488-95. PubMed ID: 24156021
[TBL] [Abstract][Full Text] [Related]
13. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
Hsueh CT; Kelsen D; Schwartz GK
Clin Cancer Res; 1998 Sep; 4(9):2201-6. PubMed ID: 9748140
[TBL] [Abstract][Full Text] [Related]
14. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Abu Lila AS; Moriyoshi N; Fukushima M; Huang CL; Wada H; Ishida T
Cancer Lett; 2017 Aug; 400():223-231. PubMed ID: 27838412
[TBL] [Abstract][Full Text] [Related]
15. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
16. Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
Yang D; Qu J; Qu X; Cao Y; Xu L; Hou K; Feng W; Liu Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):575-86. PubMed ID: 26208739
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Eto M; Inokuchi J; Kuroiwa K; Kiyoshima K; Naito S
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1557-64. PubMed ID: 21544629
[TBL] [Abstract][Full Text] [Related]
19. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells.
Tamatani T; Ferdous T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Nagai H; Fujisawa K; Miyamoto Y
Int J Oncol; 2012 Sep; 41(3):1148-56. PubMed ID: 22766915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]